Video object removal has achieved advanced performance due to the recent success of video generative models. However, when addressing the side effects of objects, \textit{e.g.,} their shadows and reflections, existing works struggle to eliminate these effects for the scarcity of paired video data as supervision. This paper presents \method, termed \textbf{R}emove \textbf{O}bjects with \textbf{S}ide \textbf{E}ffects, a framework that systematically studies the object's effects on environment, which can be categorized into five common cases: shadows, reflections, light, translucency and mirror. Given the challenges of curating paired videos exhibiting the aforementioned effects, we leverage a 3D rendering engine for synthetic data generation. We carefully construct a fully-automatic pipeline for data preparation, which simulates a large-scale paired dataset with diverse scenes, objects, shooting angles, and camera trajectories.

The integration of logic programs with embedding models resulted in a class of neurosymbolic frameworks that jointly learn symbolic rules and representations for the symbols in the logic (constant or predicate). The key idea that enabled this integration was the differentiable relaxation of unification, the algorithm for variable instantiation during inference in logic programs. Unlike unification, its relaxed counterpart exploits the similarity between symbols in the embedding space to decide when two symbols are semantically equivalent. We show that this similarity between symbols violates the transitive law of equivalence, leading to undesirable side effects in learning and inference. To alleviate those side effects, we are the first to revamp the well-known possible world semantics of probabilistic logic programs into new semantics called equivalence semantics. In our semantics, a probabilistic logic program induces a probability distribution over all possible equivalence relations between symbols, instead of a probability distribution over all possible subsets of probabilistic facts. We propose a factorization of the equivalence distribution using latent random variables and characterize its expressivity. Additionally, we propose both exact and approximate techniques for reasoning in our semantics. Experiments on well-known benchmarks show that the equivalence semantics leads to neurosymbolic models with up to 42% higher results than state-of-the-art baselines.

This material may not be published, broadcast, rewritten, or redistributed. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset . Powered and implemented by FactSet Digital Solutions . Mutual Fund and ETF data provided by LSEG . Apple's $250M Siri settlement: Are you owed cash?

While the United States and Europe are moving cautiously forward with clinical trials, China is racing toward the commercialization of brain implants. China has made history by becoming the first nation to approve a commercially available brain chip to treat a disability. NEO, the implant developed by Neuracle Medical Technology, translates the thoughts of a person with paralysis into movements of an assistive robotic hand. After 18 months of testing that proved its safety, China's National Medical Products Administration authorized the implant for people aged 19 to 60 with paralysis caused by neck or spinal cord injuries that prevent them from moving their limbs. According Nature, the implant embedded in the skull is about the size of a coin.

Neural Information Processing Systems http://nips.cc/

Intoyenvironments, Attainable Utility Preservation (AUP)avoided side effects by penalizing shifts in the ability to achieve randomly generated goals [22]. We scale this approach to large, randomly generated environments based onConway'sGame ofLife.

Novo Nordisk's semaglutide will soon be available in a daily pill Americans can take for weight loss. The US Food and Drug Administration today approved a pill version of the blockbuster anti-obesity drug Wegovy. Made by Novo Nordisk, the pill is taken once a day. The company's original version of Wegovy is a weekly injection. Both drugs contain the same active ingredient, semaglutide.